Walvax Biotechnology Co., Ltd. engages in the research, development, production, and sale of biopharmaceutical products. Its products include Bivalent human papillomavirus vaccine, 13-valent pneumococcal polysaccharide conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine, Haemophilus influenzae type b conjugate vaccine, Group A and Group C meningococcal polysaccharide conjugate vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company was founded on January 16, 2001 and is headquartered in Kunming, China.